Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada.
Clin Pharmacol Ther. 2010 Dec;88(6):792-5. doi: 10.1038/clpt.2010.125. Epub 2010 Aug 25.
Sixty-two codeine-prescribed breastfeeding mothers from a pharmacogenetic study were interviewed regarding the communication of individual CYP2D6 genotype results and overall research findings. All participants wanted to receive the results of their individual genetic tests; however, individuals placed different values on the usefulness of this information toward future medical decisions. Receiving one's pharmacogenetic test results was not associated with a negative psychosocial impact. Thirty-three percent of the participants wished to withhold these results from their physicians. Participants' expectations seem to dictate the extent of transparency of pharmacogenetic research results.
从一项药物遗传学研究中抽取了 62 位接受可待因处方治疗的母乳喂养母亲，对她们进行了关于个体 CYP2D6 基因型结果和整体研究结果的沟通情况进行了访谈。所有参与者都希望获得他们个体基因检测的结果；然而，个体对这些信息对未来医疗决策的有用性有不同的看法。获得个体药物遗传学检测结果并不会对心理社会产生负面影响。33%的参与者希望向他们的医生隐瞒这些结果。参与者的期望似乎决定了药物遗传学研究结果透明度的程度。
